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The primary use of PTFE covered stents for treatment of infrarenal occlusive disease of the abdominal aorta is
safe and provides a valid alternative for surgical reconstruction, as the complication and morbidity rates are very
low and patency rates are excellent.Background: Arterial insufﬁciency is rarely caused by isolated infrarenal aortic occlusive lesions. Endovascular
treatment options include plain balloon angioplasty and bare metal stent placement. In this study the feasibility
and efﬁcacy of polytetraﬂuoroethylene (PTFE) covered balloon expandable stents were evaluated.
Material and methods: Consecutive patients from two centers were prospectively collected in a database and
retrospectively analyzed. Results were evaluated by clinical examination, ankle-brachial indices (ABI), duplex
ultrasound, and plain abdominal radiography.
Results: Thirty-six consecutive patients were treated between November 2008 and June 2013. Indication for
treatment was Rutherford 3 (n ¼ 29), 4 (n ¼ 3), and 5 (n ¼ 4). Technical success was always achieved and there
were no distal embolizations or vessel wall ruptures. The median follow-up was 22 months (range 0e60). All
patients improved clinically and the ABI increased signiﬁcantly from 0.73  0.18 to 1.01  0.14 (p < .01). One
patent covered stent was removed surgically because of infection. Primary patency rates were 100% at 1 and 2
years without stent fractures.
Conclusion: The use of PTFE covered stents for the treatment of isolated infrarenal aortic occlusive disease is safe
and very effective. Patency rates are excellent and complications including distal embolization and vessel wall
rupture are extremely rare.
 2014 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Since the early 1980s endovascular treatment of aorto-iliac
occlusive disease has been widely applied, mostly in the
iliac arteries. Although isolated occlusive disease of the
infrarenal aorta is rare, it may cause arterial insufﬁciency
leading to (disabling) claudication or even critical limb
ischemia. Surgical treatment options include aortic bypass
grafting and endarterectomy that are associated with
outstanding patency rates of up to 86.3% at 5 years.1
However, surgical reconstruction is associated with a 8.3e
12.2% complication rate and a 3.3e4.4% mortality rate.2
Regardless of the improved quality of postoperative care,
the mortality rate of open surgical repair has not decreased
during the last decades. After surgery, late complicationsrresponding author. M.M.P.J. Reijnen, Department of Surgery, Rijn-
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//dx.doi.org/10.1016/j.ejvs.2014.08.009may also occur and include incisional hernia with an inci-
dence of 9.8%3 and postsurgical adhesion formation. Ad-
hesions are known to be the most important cause of small
bowel obstruction, a problem that is related to inadvertent
enterotomies, a higher rate of intensive care treatment and
prolonged hospital stay in case of a re-laparotomy.4 Possible
reduction in early and late complications, in combination
with the persistent mortality rate, justify the search for
minimally invasive alternatives.
Endovascular alternatives, including plain balloon angio-
plasty and primary bare metal stent placement, are
described in case series only. Complications of endovascular
treatment include vessel wall rupture and distal emboliza-
tion with a reported incidence of up to 10.2%.5,6 The au-
thors’ single centre initial experience with balloon-
expandable polytetraﬂuoroethylene (PTFE) covered stents
in 11 patients for this speciﬁc indication was published
previously, but given the low sample size no robust con-
clusions could be drawn.7
The use of covered stents may reduce the incidence of
complications and growing evidence suggests that covered
Figure 1. (A) Angiography of an occlusion of the infrarenal aorta in
a 65 year old male patient, suffering from disabling intermittent
claudication. Bifemoral access was obtained in this case as bilateral
involvement of the iliac ostia was expected based on preoperative
imaging. (B) Completion angiography after placement of PTFE
covered stents showing a complete recanalization of the infrarenal
aorta without residual stenosis.
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disease, possibly because of prevention of tissue ingrowth.8
In this study, the safety, feasibility, and efﬁcacy of PTFE
covered balloon-expandable stents is evaluated for isolatedfocal infrarenal occlusive disease in an extended two center
cohort of patients with a prolonged follow-up.
PATIENTS AND METHODS
Patients
In two clinics, the University Hospital of Regensburg, Ger-
many and the Rijnstate Hospital, Arnhem, The Netherlands,
patients treated for isolated occlusive lesions of the
infrarenal aorta were prospectively collected in a database
and retrospectively analyzed. Pre-treatment lesion
morphology was analyzed using CT angiography and scored
according to the TASC-2 guidelines.9 Clinical symptoms
were graded according the Rutherford classiﬁcation for
chronic ischemia.10 Demographic data, medical history, and
co-morbidity were retrieved from the medical ﬁles and
scored according to the Society for Vascular Surgery (SVS)
and American Association for Vascular Surgery (AAVS)
medical co-morbidity scoring system.11 Cardiovascular risk
management is standard practice in both clinics, including
the use of antiplatelet agents and statins when indicated.Technique
Details of the procedure have been described previously by
Bruijnen et al.7 Brieﬂy, patients are treated in a (hybrid)
operating theater or at the catheter laboratory of the
radiology department. Patients in the operating theater
receive standard antibiotic prophylaxis in contrast to the
patients treated at the department of radiology. One of the
common femoral arteries is accessed either percutaneously
or by surgical cut down under heparin prophylaxis, and a 9-
French sheath is introduced. After passing the lesion with
regular wires and catheters, a diagnostic digital subtraction
angiogram is performed (Fig. 1A). Thereafter, a 12-mm
Advanta V12 LD balloon expandable ePTFE covered stent
(Atrium Medical, Maquet Getinge Group, Hudson, NH, USA)
is expanded at the diseased segment, without predilatation.
If required, the expanded stent is post-dilated to adapt to
the aortic diameter with a 14 mm or 16 mm PTA balloon. A
completion angiogram is performed to assess for proper
deployment and outﬂow (Fig. 1B). Hemostasis is achieved
using a closure device following percutaneous access.
Post intervention, patients continue their acetylsalicylic
acid daily, unless oral anticoagulation with coumarines is
indicated for other pathology.
Follow-up consists of clinical assessment, duplex ultra-
sound, and ankle-brachial indices at 3, 6, and 12 months,
and annually thereafter. Plain abdominal X-ray is performed
at 12 and 24 months to assess for material breakdown or
migration.Deﬁnitions and statistics
The primary outcome measure was primary patency,
deﬁned as an uninterrupted patency in the absence of oc-
clusion, with no procedures performed on the vessel or
stent to prevent occlusion. A re-stenosis was deﬁned as a
lesion with a peak systolic value (PSV) ratio >2.5 as
Table 1. The incidence of cardiovascular risk factors of patients
treated with an ePTFE covered stent graft for isolated lesions in
the infrarenal aorta.
n %
ASA
1 0 0
2 15 42
3 18 50
4 3 8
Tobacco use
Never, >10 years ago 6 17
No, but <10 years ago 0 0
Yes <20/day 21 58
Yes >20/day 9 25
Diabetes mellitus
No 31 86
Adult, dietary or oral medication controlled 3 8
Adult, insulin-dependent 2 6
Juvenile diabetes 0 0
Hypertension
No 17 47
Treated by single drug 10 28
Treated by two drugs 3 8
Treated by three drugs 6 17
Hyperlipidemia
Normal lipids 10 28
Mildly elevated, dietary control 2 6
Treated with drugs 22 61
Unknown 2 6
Cardiac disease
Asymptomatic 24 67
Non recent myocardial infarction (MI) (>6 m),
asymptomatic MI on EKG (electrocardiogram)
2 6
Stable angina pectoris, arrhythmias, treatable
heart failure
4 11
Unstable angina pectoris, recent MI(<6 m) 6 17
Pulmonary disease
Asymptomatic 27 75
Mild dyspnea 3 8
Moderate dyspnea 2 6
O2-dependent, pulmonary hypertension 0 0
Unknown 4 11
Carotid disease
No disease 36 100
Asymptomatic, but sign of disease 0
TIA/stroke without temporary deﬁcit 0
TIA/stroke with permanent deﬁcit 0
Renal disease
No 27 75
GFR (glomerular ﬁltration rate)30e50 mL/min 8 22
GFR 15e30 mL/min 1 3
GFR <15 mL/min or renal transplant 0 0
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stent, or an angiographic diameter reduction of >50%.12
Secondary outcomes were assisted primary patency,
secondary patency, limb salvage rate, technical success,
clinical improvement, and complications. Terms and classi-
ﬁcations were deﬁned according to the reporting standards
of Rutherford et al.10Technical success was deﬁned as stent placement
restoring blood ﬂow with <30% residual stenosis. Clinical
improvement was deﬁned as a symptomatic improvement
of at least one Rutherford category.Statistical analysis
Statistical analysis was performed using SPSS version 19.0
(Statistical Package for the Social Sciences, Inc., Chicago, IL,
USA). Variables were expressed as mean  standard devi-
ation (SD) in the case of normal distribution, or median and
range in other distributions. In all patients the mean ABI of
both legs was calculated to compare pre- and post-
procedural ABI with paired t tests. Also, the highest ABI
before the procedure was compared with the post-
procedural ABI at the same leg with paired t tests.
Patency rates and limb salvage rates were estimated using
the KaplaneMeier survival analysis. Probability values given
are based on two-sided analyses of test results. A signiﬁ-
cance level of 5% was used.RESULTS
In the period of November 2008 to June 2013, 36 consec-
utive patients, 13 males and 23 females, with isolated
infrarenal aortic occlusive disease were treated with a
balloon expandable covered stent in the two clinics. During
the same period no other patients were treated with either
plain balloon angioplasty or bare metal stent placement for
this speciﬁc indication. The mean age was 58 years (range
37e78 years). The co-morbidities of the study group are
listed in Table 1. Patients were classiﬁed as Rutherford 3
(n ¼ 29), 4 (n ¼ 3), or 5 (n ¼ 4).
Twenty-one procedures (58%) were performed percuta-
neously. In 15 procedures access was obtained by surgical
cut down. In 10 cases the procedure was combined with
other treatment modalities, including endarterectomy of
the common femoral artery (n ¼ 9), balloon angioplasty or
stenting of the iliac artery (n ¼ 4) or femoro-femoral
crossover bypass (n ¼ 2). Technical success was achieved
in all patients. In one patient the procedure was compli-
cated by a stent dislocation from the balloon. In this case
the stent was successfully replaced and deployed. Flow
limiting dissections occurred in two procedures (one prox-
imal, one in the iliac tract) and both were treated with
balloon angioplasty, followed by covered stent placement.
Post-procedural complications included two groin hema-
tomas, both treated conservatively. The 30-day complica-
tion rate was 6% and there was no 30-day mortality.
Clinical improvement with at least one Rutherford cate-
gory occurred in all patients. The mean ABI improved
signiﬁcantly from 0.73  0.18 before the procedure to
1.01  0.14 after the procedure (p < .01). The highest
measured ABI before the procedure also improved signiﬁ-
cantly from 0.76  0.19 to 1.03  0.14 (p < .01). During
follow-up, two patients died, both 11 months after the
procedure, one as a result of pulmonary causes, and one
following a cardiac event.
Figure 2. FDG-PET/CT scan of a 55-year-old female patient with a
Streptococcus pyogenes infection of a covered stent in the
infrarenal aorta, showing increased focal FDG uptake and thick-
ened aortic wall, suggesting edema.
Table 2. Lesion characteristics of patients treated with an ePTFE
covered balloon expandable stent for isolated lesions in the
infrarenal aorta.
Length stenosis (mm) 26 (5e58)
Percentage stenosis (percentage) 80 (50e100)
Eccentric lesion/concentric lesion 13/21a
TASC-IIb
B 17
D 19
Stent diameter (mm) 12 (10e14)
Stent length (mm) 41 (38e143)
Number of stents used
1 35
3 1
Data are presented as median and range.
a In two occlusions the lesion conﬁguration could not be classiﬁed.
b TASC-II B: stenosis <3 cm. TASC-II D: aortoiliac occlusion or
involvement that needs treatment, stenosis >3 cm was considered
TASC-II D.
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week-60 months. A follow up of 6 months was available for
32 patients, 12 months for 27 patients, and 2 years for 17
patients. During follow up all stents remained patent,
making the primary patency rate 100% during the ﬁrst 2
years. One re-intervention was performed. In this patient,
an infection of the stentgraft occurred 11 months after the
procedure, while the stent itself remained patent. The
procedure was not combined with other interventions and
was performed percutaneously. Clinical symptoms included
abdominal pain, fever, and increased infection parameters.
Blood cultures were positive for Streptococcus pyogenes.
FDG-PET/computed tomography (CT) scanning revealed an
infection at the site of the stent (Fig. 2). The stent was
surgically removed, there were no signs of re-stenosis or
occlusion, and after an endarterectomy the aorta could be
primarily closed, without patching.
Abdominal X-rays during follow-up did not show any
stent fractures, kinking, or migration in the study cohort.
There was no limb-loss during the follow up period.DISCUSSION
This two center cohort study shows that the use of PTFE
covered stents for the treatment of isolated infrarenal aortic
occlusive disease is both safe and very effective. Patency rates
are excellent and only one major complication, a stent
infection, occurred during follow up. In this series no signs of
distal embolization or vessel wall rupture were found.
The largest cohort study on endovascular treatment of
isolated infrarenal occlusive lesions to date was published
by Kim et al.6 In that study both balloon-expandable and
self-expandable bare metal stents were used to treat 49
lesions. Complications were reported in 16.3% of the pa-
tients and distal embolization occurred in 10.2%. A possible
advantage of PTFE covered stents includes the immediate
covering of ulcerated plaques and vessel wall thrombus,
thereby possibly preventing distal embolization. Moreover,
the “dog-bone” shape inﬂation of the balloon may catch
emboli behind the covering material, thus further reducing
the chances of embolization. In this cohort no distalembolization occurred, although the occurrence of sub-
clinical microemboli cannot be excluded. However, two
dissections were seen during the procedures. In one case a
dissection in the common iliac artery was treated primarily
with PTA alone, with no residual stenosis. Five weeks later
this patient presented with an occlusion of the common
iliac artery, which was treated by a self-expandable covered
stent. In the other case a ﬂow limiting dissection occurred
proximal to the stenosis in the aorta, which was treated
with an additive PTFE covered balloon expandable stent,
with overlap, without residual stenosis.
The overall 30-day complication rate in this cohort was
only 6%, which is very low compared with the other studies
(0e28.5%).5,6,1319 Post-procedural complications included
two groin hematomas, which were treated conservatively
and did not cause any clinical impairment. Furthermore,
there were no major complications or mortality in the ﬁrst
30 days, proving the safety of the technique.
The TASC-2 guidelines provide treatment strategies based
on lesion characteristics (Table 2). However, there is no TASC-
2 classiﬁcation available for stenotic lesions in the infrarenal
aorta beyond 3 cm. In the current study these lesions were
classiﬁed as TASC-2 D lesions. These lesions, however, could
also be classiﬁed as TASC-2 “C” lesions.This would render the
majority of lesions TASC-2 C and D. In theory, eccentric and
heavily calciﬁed lesions are more prone to rupture during
intervention. A possible advantage of the use of covered
stents is that they would treat any rupture instantly.
The diameter of the infrarenal aorta should be taken into
account when planning the stent diameter. A 12-mm LD
Advanta V12 is inserted through a 9-Fr sheath and can
subsequently be ﬂared to 20 mm, or not ﬂared at all.
Therefore, there are no limits to the possibilities of
adjusting stent diameters to the aortic wall.
In theory, other possible complications of the use of
covered stents are the occlusion of collateral arteries, or the
inferior mesenteric artery (IMA). In stenotic lesions, how-
ever, collateral arteries and the IMA are commonly
occluded. In this series, no visceral or spinal cord ischemic
events occurred.
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and not all data were complete. During follow up, no re-
stenosis or occlusions occurred. However, a 2-year follow
up was available for only 17 patients, which is still a rela-
tively small sample size. Given the low prevalence of these
lesions, however, larger series may be hard to collect.
Obviously, the study results should be established by a
randomized study, but again this low incidence of the pa-
thology will limit the feasibility of such a trial. One of the
procedural complications was a stent dislocation from the
balloon in one of the early patients. Thereafter, adjustments
to the device have been made by the manufacturer aimed
at reducing the risk of dislocation.
In this cohort one patient had an infected stent that had to
be surgically removed. During the initial procedure, antibiotic
prophylaxis was used and the procedure was performed
percutaneously. The necessity for antibiotic prophylaxis in
percutaneous procedures has never been shown, to the au-
thors’ knowledge, but seems to be indicated as foreign ma-
terial is implanted and the consequences of an infection may
be devastating. Covered stents may be more susceptible to
infection than bare metal stents, and, therefore, the authors
advocate implantation of the devices in a sterile environment
such as a hybrid operating theater. However, in this cohort the
patients treated at the radiology department did not receive
standard antibiotic prophylaxis.
The cost effectiveness of covered stents for aorto-iliac
occlusive disease is unclear, as these devices are usually
more expensive than the vascular grafts used in open sur-
gery or bare metal stents. However, recent analysis showed
a signiﬁcantly lower complication rate for endovascular
procedures and shorter hospital stay.20 The authors found a
signiﬁcantly lower inpatient cost for endovascular repair
compared with open repair in aorto-iliac occlusive disease.
With improving patency rates and the possible advantage of
lower long term morbidity, endovascular techniques are
becoming an attractive alternative to open repair. As
experience grows, the need for follow up imaging may be
reduced, further reducing costs for endovascular repair.
Isolated stenotic and occlusive lesions of the infrarenal
aorta can be treated well with single PTFE covered balloon
expandable stents, as described in this paper. When the
bifurcation or common iliac arteries are involved in the
lesion, the authors recommend use of the recently
described CERAB technique (Covered Endovascular Recon-
struction of the Aortic Bifurcation).21 In this technique, the
bifurcation is reconstructed with the use of three PTFE
covered stents that are placed inside each other as if they
were molded together. The ﬁrst clinical results of this
technique are awaited.Conclusion
The primary use of PTFE covered stents for the treatment of
infrarenal occlusive disease of the abdominal aorta is safe
and provides a valid alternative to surgical reconstruction,
as the complication and morbidity rates are very low and
patency rates are excellent.FUNDING
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